Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 21 open reading frame 58 (C21orf58) encodes a protein mainly localized in the nucleus and cytoplasm, characterized by conserved domains mediating protein-protein interactions[1]. C21orf58 acts as an oncogenic adaptor, facilitating the formation of a ternary complex with JAK2 and STAT3, leading to abnormal STAT3 activation, which promotes cell growth, tumorigenesis, and resistance to therapies such as sorafenib in hepatocellular carcinoma[2][3]. Its expression is low and constitutive across tissues, but can be aberrantly elevated in certain cancers and disease states[1][2][4][5]. Recent studies identify C21orf58 as a promising therapeutic target in HCC, with alminoprofen shown to inhibit its function and suppress malignancy. However, the endogenous physiological functions outside cancer contexts remain largely uncharacterized, and no paralogs have been identified in humans[1].
Inhibition of JAK2/STAT3 pathway via blockade of adaptor ternary complex formation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 21 open reading frame 58 (C21orf58).